TOKYO — Takeda Pharmaceutical plans to seek approval from U.S. regulators to sell its dengue fever vaccine, aiming to become the first Japanese company to enter the American vaccine market, Nikkei has learned.
Takeda's plan to submit an application to the US Food and Drug Administration was announced by Takeda CEO Christoph Weber. Details such as timing of documentation and production plans will be ironed out later.